中國人壽(02628.HK)擬不超20億元通過資產支持計劃購買信託貸款債權
格隆匯12月16日丨中國人壽(02628.HK)公吿,公司擬以不超過人民幣2,000,000,000元認購資產管理公司設立的資產支持計劃下每單位人民幣1元的不超過2,000,000,000份受益憑證,並擬於2021年12月31日前就此簽署認購書。資產支持計劃的全部募集資金將用於向重慶信託購買其以受託人身份所持有的信託貸款債權。
信託貸款為一項提供給徐工集團本金額為人民幣2,000,000,000元的貸款,利息為每年4.75%,用於徐工集團補充其營運資金和調整債務結構。信託貸款的期限為60個月,將於2025年5月13日到期。徐工集團應每半年支付信託貸款利息,並按照其與重慶信託所簽訂的信託貸款合同中規定的時間安排,分期支付信託貸款本金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.